Plasmapheresis treatment of antibody-mediated rejection in an A2 donor to O pediatric liver transplant recipient

Pediatric Transplantation

Volumn 15, Issue 1, 2011, Pages

  Martin, T ^a   Schwartz, J ^a   Demetris, A ^b   Comstock, J ^a   Lowichik, A ^a   Book, L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

antibody mediated rejection; humoral rejection; pediatric liver transplantation; plasmapheresis

Indexed keywords

AGGLUTININ; ALANINE AMINOTRANSFERASE; BLOOD GROUP A ANTIBODY; CYTOMEGALOVIRUS ANTIBODY; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGRAFT; ANTIBODY MEDIATED REJECTION; ANTIBODY TITER; ARTICLE; ASCITES; BILE DUCT ATRESIA; BILE DUCT INJURY; BLOOD DONOR; BLOOD GROUP A; BLOOD GROUP O; CASE REPORT; CENTRAL PERIVENULITIS; CHILD; CHOLANGITIS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; END STAGE LIVER DISEASE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALNUTRITION; PLASMAPHERESIS; PORTAL HYPERTENSION; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; SINGLE DRUG DOSE; STEROID THERAPY; VEIN DISEASE;

ADOLESCENT; BIOPSY; BLOOD GROUP INCOMPATIBILITY; END STAGE LIVER DISEASE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFLAMMATION; ISCHEMIA; LIVER TRANSPLANTATION; PLASMAPHERESIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 78751656397     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2009.01224.x     Document Type: Article

References (6)

1. Nakamura K, Murase N, Becich MJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993: 142: 1383-1391.
2. Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988: 132: 489-502.
3. Demetris AJ, Nakamura K, Yagihashi A, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992: 16: 671-681.
4. Egawa H, Uemoto S, Inomata Y, et al. Biliary complications in pediatric living related liver transplantation. Surgery 1998: 124: 901-910.
5. Takakura K, Kiuchi T, Kasahara M, et al. Clinical implications of flow cytometry crossmatch with T or B cells in living donor liver transplantation. Clin Transplant 2001: 15: 309-316.
6. Astarcioglu I, Cursio R, Reynes M, Gugenheim J,. Increased risk of antibody-mediated rejection of reduced-size liver allografts. J Surg Res 1999: 87: 258-262.